

# Federico Argenteles-Arias

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8926987/publications.pdf>

Version: 2024-02-01

85  
papers

1,986  
citations

331259

21  
h-index

264894

42  
g-index

90  
all docs

90  
docs citations

90  
times ranked

2609  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. <i>Gastroenterology</i> y <i>Hepatology</i> , 2022, 45, 165-176.	0.2	3
2	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 421.	1.0	8
3	Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1725-1736.	0.9	27
4	Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210861.	1.4	1
5	Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, , .	0.1	8
6	Native Chilean Berries Preservation and In Vitro Studies of a Polyphenol Highly Antioxidant Extract from Maqui as a Potential Agent against Inflammatory Diseases. <i>Antioxidants</i> , 2021, 10, 843.	2.2	9
7	Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2021, , .	0.6	6
8	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 606-616.	0.9	29
9	Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. <i>Nanomaterials</i> , 2020, 10, 1403.	1.9	411
10	Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1514-1522.	0.8	8
11	Polyphenolic Maqui Extract as a Potential Nutraceutical to Treat TNBS-Induced Crohn's Disease by the Regulation of Antioxidant and Anti-Inflammatory Pathways. <i>Nutrients</i> , 2020, 12, 1752.	1.7	14
12	Small Bowel Enteroscopy – A Joint Clinical Guideline from the Spanish and Portuguese Small Bowel Study Groups. <i>GE Portuguese Journal of Gastroenterology</i> , 2020, 27, 324-335.	0.3	10
13	Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 113, 92-97.	0.1	3
14	Does the Antitumor Necrosis Factor- $\alpha$ Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?. <i>Journal of Clinical Densitometry</i> , 2019, 22, 195-202.	0.5	13
15	P439 Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S329-S330.	0.6	0
16	Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481985805.	1.4	10
17	P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S328-S329.	0.6	0
18	Increased risk of thiopurine-related adverse events in elderly patients with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 780-788.	1.9	40

#	ARTICLE	IF	CITATIONS
19	P309 Impact of co-morbidities on loss and lack of response to anti-TNFs in inflammatory bowel disease: VERNE study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S254-S255.	0.6	0
20	Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1380-1386.	0.6	19
21	P127 Anti-TNFs patterns of use in clinical practice in inflammatory bowel disease (VERNE study). <i>Journal of Crohn's and Colitis</i> , 2019, 13, S151-S152.	0.6	0
22	P214 How to incorporate patients preference into ulcerative colitis current clinical management: initial document from a Spanish multidisciplinary steering committee. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S202-S203.	0.6	0
23	P424 Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S321-S322.	0.6	1
24	P094 Polyphenolic extract from Chilean berry attenuates intestinal damage and improves clinical indicators in an animal model of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S133-S133.	0.6	0
25	Differences between childhood and adulthood onset inflammatory bowel disease: the <scp>CAROUSEL</scp> study from <scp>GETECCU</scp>. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 419-428.	1.9	28
26	Role of capsule endoscopy in alarm features and non-responsive celiac disease: A European multicenter study. <i>Digestive Endoscopy</i> , 2018, 30, 461-466.	1.3	23
27	Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1815-1823.	0.8	17
28	Influence of age, body mass index and comorbidity on major outcomes in acute pancreatitis, a prospective nationwide multicentre study. <i>United European Gastroenterology Journal</i> , 2018, 6, 1508-1518.	1.6	37
29	Using Vedolizumab to Treat Severe Sweet's Syndrome in a Patient With Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1134-1135.	0.6	2
30	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1270-1279.	0.6	15
31	Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 564-570.	0.1	11
32	Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2018, 24, 5288-5296.	1.4	10
33	Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 407.	0.1	1
34	Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 792-800.	0.6	16
35	Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1305-1312.	1.1	40
36	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 120-131.	0.2	93

#	ARTICLE	IF	CITATIONS
37	Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1290-1295.	0.8	37
38	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1430-1439.	0.6	123
39	Capsule endoscopy in young patients with iron deficiency anaemia and negative bidirectional gastrointestinal endoscopy. <i>United European Gastroenterology Journal</i> , 2017, 5, 974-981.	1.6	35
40	Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1394-1402.	0.9	71
41	Perceived Emotional and Psychological Impact of Ulcerative Colitis on Outpatients in Spain: UC-LIFE Survey. <i>Digestive Diseases and Sciences</i> , 2017, 62, 207-216.	1.1	20
42	Knowledge of disease and access to a specialist reported by Spanish patients with ulcerative colitis. UC-LIFE survey. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 421-429.	0.1	3
43	Evolution of the incidence of inflammatory bowel disease in Southern Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 757-760.	0.1	7
44	A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 552-558.	0.1	15
45	Role of capsule endoscopy in suspected celiac disease: A European multi-centre study. <i>World Journal of Gastroenterology</i> , 2017, 23, 703.	1.4	24
46	Tu1996 Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicenter Study. <i>Gastroenterology</i> , 2016, 150, S1000-S1001.	0.6	0
47	P-044 Outcomes of Tuberculin Skin Test in Routine Screening for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, S23.	0.9	0
48	Tu1925 Real-Life Experience With Golimumab in Ulcerative Colitis Patients According to Prior Anti-TNF Use. <i>Gastroenterology</i> , 2016, 150, S979.	0.6	3
49	Perception of disease burden and treatment satisfaction in patients with ulcerative colitis from outpatient clinics in Spain: UC-LIFE survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1056-1064.	0.8	21
50	Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. <i>International Journal of Colorectal Disease</i> , 2016, 31, 543-551.	1.0	106
51	Initial experience with golimumab in clinical practice for ulcerative colitis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 108, 129-32.	0.1	13
52	A survey-based analysis on endoscopic quality indicators compliance among Spanish endoscopists. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 109, 33-48.	0.1	3
53	How is inflammatory bowel disease managed in Spanish gastroenterology departments? The results of the GESTIONA-EII survey. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 108, 618-626.	0.1	2
54	Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines Withdrawal. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1564-1571.	0.9	23

#	ARTICLE	IF	CITATIONS
55	The management of lactose intolerance among primary care physicians and its correlation with management by gastroenterologists: The SEPD-SEMG national survey. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 107, 554-8.	0.1	8
56	Guideline for wireless capsule endoscopy in children and adolescents: A consensus document by the SEGHN (Spanish Society for Pediatric Gastroenterology, Hepatology, and Nutrition) and the SEPD (Spanish Society for Digestive Diseases). <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 107, 714-31.	0.1	30
57	Results of a nation-wide survey on hypolactasia-how is this condition diagnosed and managed in our setting?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 107, 55-6.	0.1	0
58	Capsule Endoscopy in the Small Bowel Crohn's Disease. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-8.	0.7	9
59	Colon capsule endoscopy is a safe and useful tool to assess disease parameters in patients with ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 894-901.	0.8	23
60	Capsule endoscopy in patients refusing conventional endoscopy. <i>World Journal of Gastroenterology</i> , 2014, 20, 7424.	1.4	19
61	Author's answer: biosimilar therapy for inflammatory bowel disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2014, 106, 67-67.	0.1	2
62	Preparations for colon capsule endoscopy. Prospective and randomized comparative study between two preparations for colon capsule endoscopy: PEG 2 liters + ascorbic acid versus PEG 4 liters. <i>Revista Espanola De Enfermedades Digestivas</i> , 2014, 106, 312-7.	0.1	18
63	Retroperitoneal hematoma in Crohn's disease patient with warfarin therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2014, 106, 364-6.	0.1	2
64	Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2949-2954.	1.1	62
65	Spectral properties and energy transfer in Er <sup>3+</sup> /Yb <sup>3+</sup> co-doped LiYF <sub>4</sub> crystal. <i>Optoelectronics Letters</i> , 2013, 9, 285-288.	0.4	6
66	Mol111 Efficacy of Preoperative Administration of Ferric Carboxymaltose in Colon Cancer Patients and Anemia. <i>Gastroenterology</i> , 2013, 144, S-581.	0.6	1
67	Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of) Tj ETQq1 1 0.784314 rgBT /Overlock 1011 biosimilar therapy for inflammatory bowel disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2013, 105, 37-43.	0.1	58
68	Is safety infliximab during pregnancy in patients with inflammatory bowel disease?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 59-64.	0.1	24
69	Lycium barbarum: A new hepatotoxic "natural" agent?. <i>Digestive and Liver Disease</i> , 2011, 43, 749.	0.4	13
70	Residual hydrocephalus after tuberculous meningitis in a patient with biological therapy. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E33-E34.	0.9	2
71	Dysphagia caused by migrated mesh after paraesophageal hernia repair. <i>Endoscopy</i> , 2011, 43, E257-E258.	1.0	9
72	Dysphagia caused by migrated mesh after paraesophageal hernia repair. <i>Endoscopy</i> , 2011, 43, E314-E314.	1.0	0

#	ARTICLE	IF	CITATIONS
73	PillCam <sup>®</sup> Colon Capsule for the study of colonic pathology in clinical practice: Study of agreement with colonoscopy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 69-75.	0.1	19
74	Should anorectal ultrasonography be included as a diagnostic tool for chronic anal pain?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2010, 102, 7-14.	0.1	8
75	Results of a survey about specific inflammatory bowel disease units in Andalusia. <i>Revista Espanola De Enfermedades Digestivas</i> , 2009, 101, 187-94.	0.1	5
76	¿Es útil la cápsula endoscópica en niños con dolor abdominal crónico?. <i>Anales De Pediatría</i> , 2007, 67, 385-389.	0.3	1
77	Limitations in Capsule Endoscopy Examinations. <i>Gastrointestinal Endoscopy</i> , 2006, 63, AB114.	0.5	1
78	Results of a survey in Andalusian Endoscopy Units. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006, 98, 929-48.	0.1	5
79	The Value of Capsule Endoscopy in Pediatric Patients with a Suspicion of Crohn's Disease. <i>Endoscopy</i> , 2004, 36, 869-873.	1.0	120
80	Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 78-84.	2.4	63
81	Screening of Hepatocellular Carcinoma in Autoimmune Cirrhosis: More Value Than Costs?. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 830-831.	1.1	2
82	Antiinflammatory Agents Less Dangerous for Gastrointestinal Tract. <i>Current Pharmaceutical Design</i> , 2001, 7, 951-976.	0.9	13
83	Accidental Intrarectal Administration of Alcohol Enema Induces Proctocolitis and Fecal Incontinence. <i>Endoscopy</i> , 2001, 33, 641-641.	1.0	6
84	Acute Cholestatic Hepatitis in A Child Treated With Famotidine. <i>American Journal of Gastroenterology</i> , 2000, 95, 3665-3666.	0.2	11
85	How can we prevent colorectal cancer with ursodeoxycholic acid?. , 0, , 201-206.		0